Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the
law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the
proposed sale of Celgene Corporation (“Celgene”) (NasdaqGS: CELG) to
Bristol-Myers Squibb Company (“Bristol-Myers”) (NYSE: BMY). Under the
terms of the proposed transaction, shareholders of Celgene will receive
only $50.00 in cash and 1.0 shares of Bristol-Myers for each share of
Celgene that they own. KSF is seeking to determine whether this
consideration and the process that led to it are adequate, or whether
the consideration undervalues the Company.
If you believe that this transaction undervalues the Company and/or if
you would like to discuss your legal rights regarding the proposed sale,
you may, without obligation or cost to you, e-mail or call KSF Managing
Partner Lewis S. Kahn (firstname.lastname@example.org)
toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-celg/
to learn more.
To learn more about KSF, whose partners include the Former Louisiana
Attorney General, visit www.ksfcounsel.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190211005788/en/